Testing for MSI/MMR status at diagnosis; a key for the 1L treatment of eligible patients with advanced CRC
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]
Length: 06:21
A short video detailing the testing data on KEYNOTE-177, which highlights how determining MSI/MMR status is an important step for your patients with advanced CRC and can help identify potential eligibility for KEYTRUDA® (pembrolizumab).
More information about KEYTRUDA® (pembrolizumab) in metastatic CRC
Supporting documentation
Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland)
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website